Galmed Pharma Regains Nasdaq Listing Compliance
Ticker: GLMD · Form: 6-K · Filed: Sep 16, 2024 · CIK: 1595353
| Field | Detail |
|---|---|
| Company | Galmed Pharmaceuticals LTD. (GLMD) |
| Form Type | 6-K |
| Filed Date | Sep 16, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $1.00 |
| Sentiment | bullish |
Sentiment: bullish
Topics: compliance, listing, nasdaq
Related Tickers: GLMD
TL;DR
Galmed Pharma is back in Nasdaq's good graces, shares stay listed!
AI Summary
On September 16, 2024, Galmed Pharmaceuticals Ltd. received notification from the Nasdaq Listing Qualifications Staff that it has regained compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)). As a result, the Company's ordinary shares will continue to be listed and traded on the Nasdaq Stock Market, and it is now in compliance with all applicable listing standards.
Why It Matters
This news is crucial for investor confidence as it ensures the continued trading of Galmed's shares on a major stock exchange, preventing potential delisting.
Risk Assessment
Risk Level: low — The filing confirms compliance with Nasdaq listing rules, removing immediate delisting concerns.
Key Players & Entities
- Galmed Pharmaceuticals Ltd. (company) — Company receiving notification
- Nasdaq Listing Qualifications Staff (company) — Entity issuing notification
- Nasdaq Stock Market (company) — Exchange where shares are traded
- September 16, 2024 (date) — Date of notification
- Nasdaq Listing Rule 5550(a)(2) (rule) — Specific rule requirement regained
FAQ
What specific Nasdaq listing rule did Galmed Pharmaceuticals Ltd. regain compliance with?
Galmed Pharmaceuticals Ltd. regained compliance with Nasdaq Listing Rule 5550(a)(2), which pertains to the minimum bid price requirement.
When did Galmed Pharmaceuticals Ltd. receive this notification from Nasdaq?
The notification was received on September 16, 2024.
What is the immediate impact of this notification on Galmed Pharmaceuticals Ltd.'s stock?
The immediate impact is that Galmed Pharmaceuticals Ltd.'s ordinary shares will continue to be listed and traded on the Nasdaq Stock Market.
Is Galmed Pharmaceuticals Ltd. now in compliance with all Nasdaq listing standards?
Yes, the filing states that the Company is now in compliance with all applicable listing standards.
What was the previous concern regarding Galmed Pharmaceuticals Ltd.'s listing on Nasdaq?
The previous concern was related to not meeting the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).
Filing Stats: 324 words · 1 min read · ~1 pages · Grade level 10.9 · Accepted 2024-09-16 16:15:24
Key Financial Figures
- $1.00 — iled to maintain a minimum bid price of $1.00 for 30 consecutive business days. To re
Filing Documents
- form6-k.htm (6-K) — 16KB
- 0001493152-24-036393.txt ( ) — 17KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Galmed Pharmaceuticals Ltd. Date: September 16, 2024 By: /s/ Allen Baharaff Allen Baharaff President and Chief Executive Officer